JANET GIANINO: Open Payments
NPI 1386058378 · LEAWOOD, KS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$837 in 45 payments from 17 companies in 2025. Trend: 2023 $991 · 2024 $816 · 2025 $837
Food & beverage: $837
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 15 | $318 |
| Lilly USA, LLC | 5 | $97 |
| PFIZER INC. | 3 | $52 |
| Axsome Therapeutics, Inc. | 3 | $50 |
| AstraZeneca Pharmaceuticals LP | 3 | $49 |
| Amgen Inc. | 3 | $46 |
| Novartis Pharmaceuticals Corporation | 2 | $34 |
| Kowa Pharmaceuticals America, Inc. | 2 | $31 |
| Teva Pharmaceuticals USA, Inc. | 1 | $24 |
| Otsuka America Pharmaceutical, Inc. | 1 | $23 |
Products named: VRAYLAR, QULIPTA, UBRELVY, MOUNJARO, REXULTI, AIRSUPRA, LEQVIO, PREVNAR 20.
Industry payments across KS — which companies pay providers there.
